{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:14:03Z","timestamp":1792595643076,"version":"4.5.0"},"reference-count":19,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,9,11]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:p>Infections caused by <jats:italic>Ureaplasma urealyticum<\/jats:italic> in immune-competent people are typically simple and uncomplicated. However, in cases of immunosuppression, severe disseminated infections can occur.<\/jats:p>\n               <jats:p>This case report describes the case of a severe, disseminated infection caused by <jats:italic>U. urealyticum<\/jats:italic> in a young female with unacknowledged humoral immunosuppression due to treatment with ocrelizumab for multiple sclerosis.<\/jats:p>\n               <jats:p>The patient was admitted due to a recurrent episode of a tubo-ovarian abscess. Throughout the following 2\u2009months of hospitalisation, treatment with several types of antibiotics and the placement of various drains led to no improvement. As extensive investigations indicated hypogammaglobulinaemia, <jats:italic>U. urealyticum<\/jats:italic> was suspected, and tests came back positive. Treatment with doxycycline and moxifloxacin led to a full recovery.<\/jats:p>\n               <jats:p>This demonstrates how humoral immunosuppression is a risk factor for severe disseminated infections and how these may be avoided through monitoring of immunoglobulin levels in patients treated with ocrelizumab.<\/jats:p>","DOI":"10.1136\/bcr-2023-256029","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T13:05:52Z","timestamp":1695733552000},"page":"e256029","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Severe <i>Ureaplasma urealyticum<\/i> infection in a patient with ocrelizumab-induced hypogammaglobulinaemia"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6940-8863","authenticated-orcid":false,"given":"Emma Elisabeth","family":"Poulsen","sequence":"first","affiliation":[{"name":"Clinical Institute, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Jensen-Fangel","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4629-5679","authenticated-orcid":false,"given":"Frauke","family":"Rudolf","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark"},{"name":"Clinical institute, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"2025082722044795000_16.9.e256029.1","first-page":"357","article-title":"Pelvic inflammatory disease: diagnosis, management, and prevention","volume":"100","author":"Curry","year":"2019","journal-title":"Am Fam Physician"},{"key":"2025082722044795000_16.9.e256029.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.2010.01480.x"},{"key":"2025082722044795000_16.9.e256029.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2012.06.001"},{"key":"2025082722044795000_16.9.e256029.4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4103\/0255-0857.154850","article-title":"Ureaplasma: Current perspectives","volume":"33","author":"Kokkayil","year":"2015","journal-title":"Indian J Med Microbiol"},{"key":"2025082722044795000_16.9.e256029.5","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02990-13"},{"key":"2025082722044795000_16.9.e256029.6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ofid\/ofz399","article-title":"Invasive Ureaplasma infection in patients receiving Rituximab and other humoral Immunodeficiencies-A case report and review of the literature","volume":"6","author":"Jhaveri","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025082722044795000_16.9.e256029.7","unstructured":"Region Nordjylland . Aktinomykose: Region Nordjylland:Aalborg Universitetshospital:Klinik Diagnostik:Klinisk Mikrobiologi, Available: https:\/\/pri.rn.dk\/Sider\/15631.aspx"},{"key":"2025082722044795000_16.9.e256029.8","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and other Cd20(+) B-cell-Depleting therapies in multiple sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"key":"2025082722044795000_16.9.e256029.9","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/14740338.2020.1807002","article-title":"Safety profile of Ocrelizumab for the treatment of multiple sclerosis: a systematic review","volume":"19","author":"Ng","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2025082722044795000_16.9.e256029.10","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9010012","article-title":"Safety of newer disease modifying therapies in multiple sclerosis","volume":"9","author":"Jalkh","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2025082722044795000_16.9.e256029.11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11910-017-0800-8","article-title":"Infections in patients receiving multiple sclerosis disease-modifying therapies","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2025082722044795000_16.9.e256029.12","doi-asserted-by":"crossref","first-page":"103798","DOI":"10.1016\/j.msard.2022.103798","article-title":"Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with Ocrelizumab","volume":"62","author":"Habek","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2025082722044795000_16.9.e256029.13","doi-asserted-by":"crossref","first-page":"102323","DOI":"10.1016\/j.msard.2020.102323","article-title":"Is serological response to SARS-Cov-2 preserved in MS patients on Ocrelizumab treatment? A case report","volume":"44","author":"Lucchini","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2025082722044795000_16.9.e256029.14","doi-asserted-by":"crossref","first-page":"102315","DOI":"10.1016\/j.msard.2020.102315","article-title":"Attenuation of antibody response to SARS-Cov-2 in a patient on Ocrelizumab with Hypogammaglobulinemia","volume":"44","author":"Conte","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2025082722044795000_16.9.e256029.15","first-page":"16","article-title":"An immunocompromised woman in her twenties with abdominal pain and vaginal discharge","volume":"140","author":"Kvalvik","year":"2020","journal-title":"Tidsskr Nor Laegeforen"},{"key":"2025082722044795000_16.9.e256029.16","unstructured":"The\u00f3d\u00f3rsd\u00f3ttir \u00c1 , Christensen JR , Dansk Neurologisk Selskab . Ocrelizumab Behandling Af MS. neurologiske Nationale Behandlingsvejledning, nNBV, Available: https:\/\/nnbv.dk\/ocrelizumab-behandling-af-ms\/ [Accessed 10 Nov 2022]."},{"key":"2025082722044795000_16.9.e256029.17","unstructured":"Ocrevus: EPAR - product information . European Medicines Agency; 2018. Available: https:\/\/www.ema.europa.eu\/documents\/product-information\/ocrevus-epar-product-information_en.pdf [Accessed Oct 2022]."},{"key":"2025082722044795000_16.9.e256029.18","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP) . Ocrevus: EPAR - public assessment report; 2018. Available: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ocrevus-epar-public-assessment-report_en.pdf [Accessed 3 Oct 2022]."},{"key":"2025082722044795000_16.9.e256029.19","unstructured":"OCREVUS\u00ae (Ocrelizumab) injection, for intravenous use . U.S. Food and Drug Administration; 2022. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761053s029s030lbl.pdf [Accessed 3 Oct 2022]."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-256029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:05:00Z","timestamp":1756357500000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-256029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,26]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/bcr-2023-256029"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-256029","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}